Featuring an interview with Ms Jennifer Filipi, including the following topics:

• Responsibilities of an oncology nurse and perspectives on the career (0:00)
• Case: A woman in her late 70s with BRCA1-mutated ovarian cancer (OC) (3:50)
• Case: A woman in her mid 40s, a mother of 3, with advanced OC (27:23)
• Case: A woman in her early 70s, a social worker, with platinum-refractory OC (40:02)

NCPD information and select publications

Featuring perspectives from Dr Ajay K Nooka and Dr Paul G Richardson, including the following topics:

• Introduction: ASCO 2025 Showstoppers (0:00)
• Up-Front Treatment of Multiple Myeloma (MM) — Survey Questions (5:50)
• Emerging Novel Therapies for Relapsed/Refractory (R/R) MM — Faculty Presentation (11:57)
• Emerging Novel Therapies for R/R MM — Survey Questions (26:19)
• Current Management of R/R MM — Faculty Presentation (38:34)
• Current Management of R/R MM — Survey Questions (49:20)

CME information and select publications

Featuring perspectives from Prof Marina Chiara Garassino, Dr John V Heymach, Prof Solange Peters and Dr Jacob Sands, moderated by Dr Sands, including the following topics:

• Introduction (0:00)
• Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters (2:07)
• Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino (26:30)
• Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands (50:19)
• Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach (1:12:36)

CME information and select publications

Featuring perspectives from Dr Haley Ellis, Dr Sara Lonardi and Dr Kanwal Raghav, moderated by Dr Christopher Lieu, including the following topics:

• Introduction (0:00)
• Gastroesophageal Cancers — Dr Lonardi (1:54)
• Biliary Tract Cancers — Dr Ellis (39:20)
• Colorectal Cancer — Dr Raghav (1:07:10)

CME information and select publications

Featuring perspectives from Dr Jacqueline Broadway-Duren, Dr Bita Fakhri, Ms Corinne Hoffman and Dr Jeff Sharman, including the following topics:

• Introduction: Key Factors in the Management of Chronic Lymphocytic Leukemia (CLL) (0:00)
• Role of Covalent Bruton Tyrosine Kinase (BTK) Inhibitors for Newly Diagnosed CLL (12:02)
• Role of Time-Limited Up-Front Treatment, Including Therapy Combining BTK Inhibitors and Venetoclax, for Newly Diagnosed CLL (37:55)
• Role of Pirtobrutinib for Relapsed/Refractory (R/R) CLL (1:02:07)
• CAR (Chimeric Antigen Receptor) T-Cell Therapy for R/R CLL (1:16:48)

NCPD information and select publications

Featuring perspectives from Dr Matthew D Galsky, Prof Andrea Necchi and Prof Thomas Powles, moderated by Dr Galsky, including the following topics:

• Introduction (0:00)
• Current and Future Management of Muscle-Invasive Bladder Cancer — Prof Powles (1:14)
• Novel Intravesical Therapies Under Evaluation for Nonmetastatic Urothelial Bladder Cancer (UBC) — Prof Necchi (24:48)
• Selection and Sequencing of Therapy for Metastatic UBC — Dr Galsky (44:52)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Christopher Flowers, Dr Ann LaCasce and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics:

• Introduction (0:00)
• Selection and Sequencing of Available Therapies for Diffuse Large B-Cell Lymphoma — Dr Flowers (2:24)
• Evolving Management Paradigm for Mantle Cell Lymphoma — Dr Phillips (31:53)
• Integration of Novel Therapies into the Management of Follicular Lymphoma — Dr LaCasce (54:51)
• Integrating Bispecific Antibodies into the Management of Non-Hodgkin Lymphoma (NHL) — Dr Brody (1:11:22)
• Current Role of CAR T-Cell Therapy in Various NHL Subtypes — Dr Abramson (1:37:55)

CME information and select publications

Featuring perspectives from Dr Anne Chiang, Ms Elizabeth Krueger, Ms Beth Sandy and Dr Erin Schenk, including the following topics:

• Introduction: Overview of Bispecific Antibodies (0:00)
• Biology of Small-Cell Lung Cancer (SCLC) and Review of Its Initial Management (13:37)
• Case: 63-year-old man — Ms Krueger (23:36)
• Current Role of Tarlatamab in Therapy for SCLC (33:40)
• Case: 70-year-old woman — Ms Sandy (43:41)
• Future Directions in the Management of SCLC (50:45)
• Case: 81-year-old man — Ms Krueger (1:01:24)
• Unique Considerations in SCLC Management (1:09:29)
• Case: 67-year-old woman — Ms Sandy (1:22:53)

NCPD information and select publications